NECTAR 2021

This event brought together scientists, clinicians, patient advocates and industry partners from across Europe and the international community to share the latest research in repairing the damage to the central nervous system as a result of degenerative diseases. Our Deputy Director of Research, Dr Simon…


News Research news

The clinical trials pipeline for Parkinson’s: 2020/21

Despite the difficulties throughout 2020, a significant amount of clinical trial activity for Parkinson’s was conducted and a new report – involving the research team at Cure Parkinson’s – highlights the landscape of therapeutics being developed for Parkinson’s.


Farnesol: The farnesylator of PARIS

A build up of “PARkin Interacting Substrate” (or PARIS) protein has been proposed as one potential mediator of the pathology observed in some cases of Parkinson’s. The accumulation of this protein leads to the inhibition of a key protein called PGC-1α, which is a neuroprotective protein that helps to keep cells […]


News Fundraising news

The Henley Mermaids take on the Bristol Channel

On 20 July, Laura Reineke, Jo Robb, Fiona Print, Susan Barry and Joan Fennelly, otherwise known as the Henley Mermaids, swam 61km across the Bristol Channel in support of Cure Parkinson’s and three other charities dedicated to neurological conditions. The Henley Mermaids are a group…


The Bluerockers have started

On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had been dosed (Click here to read the press release). The initiation of this clinical trial by the company is a major step forward […]